NPM1
Invivoscribe, Kronos Bio Partner on Companion Diagnostic Test for Leukemia Drug
The companion diagnostic assay would identify mutations in the NPM1 gene, which Kronos Bio is targeting with its investigational drug entospletinib.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.